Literature DB >> 1556365

Leuko-araiosis and cerebral hypoperfusion compared in elderly normals and Alzheimer's dementia.

J Kawamura1, J S Meyer, Y Terayama, S Weathers.   

Abstract

OBJECTIVE: To elucidate the pathogenesis of leuko-araiosis in patients with Alzheimer's disease by utilizing CT densitometry of the brain and measurements of local perfusion in order to quantify the extent of leuko-araiosis and local hypoperfusion compared with similar measurements made among age-matched normal volunteers.
DESIGN: Cross-sectional case-control study.
SETTING: Out-patient visits to a specialized laboratory located in a large hospital facility. PATIENTS: Eighteen elderly patients with probable dementia of Alzheimer type (DAT, aged 71.8 +/- 5.1 years) and 17 neurologically and cognitively normal, age-matched volunteers (aged 68.2 +/- 9.6 years) were admitted to the study according to established criteria. INTERVENTION: None MAIN OUTCOME MEASURES: Cerebral blood flow (mL/100 g brain/min) estimated by the xenon inhalation CT-CBF method correlated with volume percentage ratio (%) measured by CT densitometry for leuko-araiosis, compared to normal white and gray matter.
RESULTS: Perfusion values for frontal and occipital white matter as well as frontal, parietal, temporal, and occipital cortex were all decreased in DAT patients. Ratios for leuko-araiosis to total brain tissue volumes were greater among patients with DAT compared with age-matched normal volunteers. White matter perfusion in zones of leuko-araiosis was decreased to a similar degree in both DAT and elderly normal volunteers.
CONCLUSIONS: Perfusion is reduced to the same degree in regions of leuko-araiosis in elderly normals as in DAT patients, but the extent of leuko-araiosis is greater among DAT patients and presumably contributes to cognitive impairments.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1556365     DOI: 10.1111/j.1532-5415.1992.tb02138.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  7 in total

1.  Alzheimer disease periventricular white matter lesions exhibit specific proteomic profile alterations.

Authors:  Eduardo M Castaño; Chera L Maarouf; Terence Wu; Maria Celeste Leal; Charisse M Whiteside; Lih-Fen Lue; Tyler A Kokjohn; Marwan N Sabbagh; Thomas G Beach; Alex E Roher
Journal:  Neurochem Int       Date:  2012-12-08       Impact factor: 3.921

2.  Effect of white matter disease on functional connections in the aging brain.

Authors:  A F Leuchter; J J Dunkin; R B Lufkin; Y Anzai; I A Cook; T F Newton
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

3.  Subjects harboring presenilin familial Alzheimer's disease mutations exhibit diverse white matter biochemistry alterations.

Authors:  Alex E Roher; Chera L Maarouf; Michael Malek-Ahmadi; Jeffrey Wilson; Tyler A Kokjohn; Ian D Daugs; Charisse M Whiteside; Walter M Kalback; Mimi P Macias; Sandra A Jacobson; Marwan N Sabbagh; Bernardino Ghetti; Thomas G Beach
Journal:  Am J Neurodegener Dis       Date:  2013-09-18

Review 4.  Some methodological issues in neuroradiological research in psychiatry.

Authors:  T Becker; W Retz; E Hofmann; G Becker; E Teichmann; W Gsell
Journal:  J Neural Transm Gen Sect       Date:  1995

5.  Alzheimer disease and subcortical ischemic vascular dementia: evaluation by combining MR imaging segmentation and H-1 MR spectroscopic imaging.

Authors:  S MacKay; F Ezekiel; V Di Sclafani; D J Meyerhoff; J Gerson; D Norman; G Fein; M W Weiner
Journal:  Radiology       Date:  1996-02       Impact factor: 11.105

6.  CT perfusion as a useful tool in the evaluation of leuko-araiosis.

Authors:  N Ramli; Kl Ho; O Nawawi; Ht Chong; Ct Tan
Journal:  Biomed Imaging Interv J       Date:  2006-04-01

7.  Melatonin Effects on EEG Activity During Sleep Onset in Mild-to-Moderate Alzheimer's Disease: A Pilot Study.

Authors:  Manuel Alejandro Cruz-Aguilar; Ignacio Ramírez-Salado; Miguel Angel Guevara; Marisela Hernández-González; Gloria Benitez-King
Journal:  J Alzheimers Dis Rep       Date:  2018-03-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.